“Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin”
“Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year.
Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as the antibiotic moxifloxacin, another pneumonia treatment. Following the encouraging results, Nabriva plans to file for FDA approval of lefamulin in the fourth quarter of 2018.
The trial, LEAP 2, compared the effects of a course of oral lefamulin to one of oral moxifloxacin administration in 738 adult patients with this type of pneumonia. The trial assessed whether the treatments could improve pneumonia symptoms and keep the patients’ overall condition stable without the use of an additional antibiotic.
Community-acquired bacterial pneumonia is one of the most common causes of infectious deaths, and its mortality rate has changed little in the last decade. The disease is most seriousin young children and people older than 65, and individuals with weakened immune systems.
The news confirms previous findings. Last year, Nabriva obtained positive results from its first Phase III clinical trial for the same antibiotic, which found lefamulin to be as effective as moxifloxacin when given with and without linezolid, an antibiotic used for drug-resistant infections.”
Source: Labiotech
